Breast

Nine Florida nonprofit programs, organizations and individuals receive Florida Blue Foundation Sapphire Award for community health improvement and share $525,000 in support

Retrieved on: 
Thursday, April 4, 2024
Health, Intellectual, Psychiatry, Organization, Parkinson's disease, Communication, Social work, Health equity, Caregiver, LMHC, Education, Patient, Inclusive, Bullying, University, Research, Breast, Food security, Doctor of Philosophy, Death, Quality of life, Student, Woman, ZIP, BSW, CCM, Self-harm, Suicide, Government, Nursing

The Florida Blue Foundation announced the winners at its annual Sapphire Awards ceremony on April 3 in Orlando.

Key Points: 
  • The Florida Blue Foundation announced the winners at its annual Sapphire Awards ceremony on April 3 in Orlando.
  • "Our Foundation recognizes the important role community-based initiatives play in strengthening neighborhoods and improving overall health and well-being," said Susan Towler, executive director of the Florida Blue Foundation.
  • The Florida Blue Foundation introduced the Sapphire Awards in 2005 to recognize excellence and innovation in community health leadership and programs across Florida.
  • Florida Blue Foundation presented the 2024 Sapphire Awards during its annual two-day Community Health Symposium.

Oklahoma Proton Center Celebrates Milestone Achievement: 5,000th Patient Successfully Treated

Retrieved on: 
Tuesday, April 2, 2024
Brain, Proton therapy, Nervous, Education, Patient, Lung, Research, Breast, Prostate, Health, Medical imaging

OKLAHOMA CITY, April 2, 2024 /PRNewswire/ -- In a momentous occasion, Oklahoma Proton Center, a leading provider of cutting-edge proton therapy, recently completed treatment on their 5,000th patient.

Key Points: 
  • OKLAHOMA CITY, April 2, 2024 /PRNewswire/ -- In a momentous occasion, Oklahoma Proton Center, a leading provider of cutting-edge proton therapy, recently completed treatment on their 5,000th patient.
  • Oklahoma Proton Center is one of a few proton centers in the country to reach the 5,000 patient milestone.
  • The Oklahoma Proton Center treats over 600 patients annually from around Oklahoma and across multiple disease sites.
  • Dr. John Chang, Medical Director at Oklahoma Proton Center remarked, "Reaching the milestone of treating our 5000th patient is a moment of great pride for our team.

Willow Expands Its Retail Presence with Target to Prepare More Breastfeeding Moms for the Early Days of Feeding

Retrieved on: 
Tuesday, April 2, 2024
Silver, Lactation, Partnership, Education, SAN, Nipple, Milk, Breast, International Board, Target Corporation, Cracked, Nursing, Find, Swelling, Birth control

SAN FRANCISCO, April 2, 2024 /PRNewswire/ -- Willow Innovations, Inc. (Willow), the Femtech leader disrupting the breastfeeding and pumping industry, announced today its expanded presence in Target to provide solutions for moms' pressing feeding challenges. Willow's comprehensive system of breastfeeding products, including its award-winning pumps and on-the-go feeding accessories, will be available in Target stores nationwide and across its digital platforms.

Key Points: 
  • With its expanded presence, Willow launched an exclusive Find Your Flow Feeding Kit , offering moms breast care essentials to prevent and relieve common breastfeeding difficulties.
  • "Moms want to be successful at breastfeeding, and Willow is redefining what comprehensive support looks like for moms at this stage," said Sarah O'Leary, CEO of Willow Innovations.
  • It is the only breastfeeding kit that combines breast care solutions, virtual lactation consultancy, personalized feeding guidance, and digital feeding courses.
  • In addition to the exclusive Willow Find Your Flow Feeding Kit ($69.99), moms can shop the award-winning Willow 360™ and Willow Go ® wearable breast pumps and other feeding accessories at your local Target store, Target.com, and onewillow.com .

Krispy Krunchy Chicken® Launches "Your Choice" Meal Deals

Retrieved on: 
Tuesday, April 2, 2024
Food, Breast, Thigh, Fast food

ATLANTA, La., April 2, 2024 /PRNewswire/ -- Krispy Krunchy Chicken®, one of the fastest growing hot food concepts in the convenience store business with nearly 3,000 locations, is letting guests customize their meal, at the ultimate price point, with the launch of their "Your Choice" Meal Deals. Starting Monday, April 1, 2024 (no, this is not a joke!), guests can visit any participating Krispy Krunchy® location for a convenient, craveable fried chicken fix. The delicious deal is available for only a limited time, so enjoy it soon!

Key Points: 
  • ), guests can visit any participating Krispy Krunchy® location for a convenient, craveable fried chicken fix.
  • Add in our incredible value and it's a winning combo," said Jim Norberg , CEO of Krispy Krunchy Chicken®.
  • The "Your Choice" Meal Deals and other Krispy Krunchy® favorites are available for pickup at your nearest location.
  • For more information about Krispy Krunchy Chicken®, visit www.krispykrunchy.com or follow on Facebook and Instagram.

THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) IS NOW ACCEPTING APPLICATIONS FOR TWO AACS CERTIFIED COSMETIC SURGERY FELLOWSHIP TRAINING PROGRAMS

Retrieved on: 
Monday, April 1, 2024
AACS, Interest, DDS, Patient, Breast, American Academy, Surgeon, Plastic surgery, Rhinoplasty, Skin, Blepharoplasty, Extremities, FACS, DMD, Physician, Dentistry

CHICAGO, April 1, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS), the world's largest multi-specialty organization for physicians dedicated to cosmetic surgery and aesthetic medicine, is accepting applications for July 2025 cohort positions for two types of AACS Certified Fellowship Training Programs. Applications are due by June 1, 2024.

Key Points: 
  • Applications for AACS Certified Cosmetic Surgery Fellowships in General Cosmetic Surgery and Facial Cosmetic Surgery, which offer comprehensive, world-class training, will be accepted until June 1, 2024 for July 2025 cohort positions
    CHICAGO, April 1, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS) , the world's largest multi-specialty organization for physicians dedicated to cosmetic surgery and aesthetic medicine, is accepting applications for July 2025 cohort positions for two types of AACS Certified Fellowship Training Programs.
  • AACS Certified Cosmetic Surgery Fellowships are the only cosmetic surgery training programs that fully prepare physicians for a career in cosmetic surgery, offering extraordinary opportunities for intensive, hands-on training in a vast array of cosmetic surgery procedures alongside some of the world's leading cosmetic surgeons.
  • Offered in General Cosmetic Surgery and Facial Cosmetic Surgery, these Certified Fellowships are post‐residency programs involving advanced education and comprehensive training in the art of general cosmetic surgery and facial cosmetic surgery.
  • Ryan Diepenbrock, DDS, FAACS, Chair of the Facial Cosmetic Surgery Fellowship Committee, adds, "AACS Fellowships provide the training needed to successfully practice as a cosmetic surgeon.

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

Retrieved on: 
Monday, April 1, 2024
HER2, IHC, CNTN4, Mutation, Genome, NSCLC, Immunotherapy, Breast, Patient, Neoplasm, ERBB2, Biomarker, Cancer, AI, Pembrolizumab, Medicine, AACR, Simple squamous epithelium, Therapy, Stomach, PD-L1, Annual general meeting

SEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, California, from April 5 to 10.

Key Points: 
  • In a poster presentation, Lunit's AI-powered HER2 analyzer, Lunit SCOPE HER2's precision shines through its analysis of 194,259 pan-cancer samples, correlating different ERBB2 mutations with changes in HER2 protein expression.
  • Through detailed HER2 intensity examination, the AI analysis highlighted that, among ERBB2-mutated cases with HER2 IHC images, a higher proportion of HER2 3+ tumor cells was observed in S310x and ex20ins cases compared to others.
  • Similarly, high HER2 expression was observed in both S301x and ex20ins cases compared to other mutation cases.
  • Visit Lunit at booth 808 to explore how the Lunit SCOPE suite is revolutionizing oncology research and clinical practice.

Statement on Increased Funding Proposal for the New York State Cancer Services Program

Retrieved on: 
Thursday, March 28, 2024
Diagnosis, Control, Assembly, Breast, Cancer, State Assembly, New Yorker, Breast cancer, Health Bureau (Macau), CSP, Birth control

ALBANY, N.Y., March 28, 2024 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization commends the State Assembly's proposed funding increase of $2.5 million for the Cancer Services Program (CSP) in the FY2025 Budget.

Key Points: 
  • ALBANY, N.Y., March 28, 2024 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization commends the State Assembly's proposed funding increase of $2.5 million for the Cancer Services Program (CSP) in the FY2025 Budget.
  • "Komen commends the New York State Assembly for investing in the wellbeing of New Yorkers and securing funding for this critical program, supporting the state's vital healthcare infrastructure."
  • If an individual is found to have cancer, CSP will navigate the individual to the NYS Medicaid Cancer Treatment Program.
  • Thank you, Susan G. Komen Breast Cancer Foundation, for your advocacy supporting CSP and to eradicate breast cancer as a life-threatening disease."

Bill Introduced in Minnesota Would Increase Access To Genetic Testing

Retrieved on: 
Thursday, March 28, 2024
Mutation, Genetic testing, Breast, Disease, Risk, Patient, Cancer, HF, Woman, Saliva, Breast cancer, Collection, Blood, Legislation

ST. PAUL, Minn., March 28, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, applauds Representative Patty Acomb (D-Minnetonka) for introducing legislation that would eliminate financial barriers to clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing.

Key Points: 
  • In Minnesota, more than 5,480 people will be diagnosed with breast cancer and 630 are expected to die of the disease in 2024 alone.
  • In the U.S., 5-10% of breast cancers are related to a known inherited gene mutation.
  • HF 5050 , introduced by Rep Acomb, eliminates the patient out-of-pocket costs for multi-gene panel testing for inherited gene mutations and evidence-based screenings, ensuring individuals have access to critical information regarding their lifetime cancer risk and recommended early detection and cancer surveillance.
  • Germline testing is a type of test that looks for inherited mutations that have been present in every cell of the body since birth.

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
Abstract, NCI, FOLFIRI, Prostate cancer, Immunotherapy, Adenocarcinoma, Colorectal cancer, PDLIM2, Physician, Patient, Lung, Biomarker, MSI, Breast, Cancer, AI, Doctor of Philosophy, Special session, MD, Lung cancer, Medicine, MBA, FOLFOX, AACR, PIM, MSS, Booth, POA, MRD, Future, Prognosis, SSP, ANTXR1, Vaccine

IRVING, Texas, March 28, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 10 studies across eight tumor types at the 2024 American Association for Cancer Research (AACR) Annual Meeting on April 5-10, 2024, in San Diego, CA, at Booth Number 1105. Caris President, David Spetzler, MS, PhD, MBA, will lead an AACR Scientist ↔ Survivor Program® Special Session titled, "Very Early Cancer Detection Assays: The Future or Fantasy," on Tuesday, April 9, from 1:00 – 1:45 PM.

Key Points: 
  • Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers.
  • (Poster Number: 7037/4)
    Poster and abstract summaries highlighting the Caris research presented at AACR 2024 will be available onsite at Caris' Booth (# 1105).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.
  • POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.

Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows

Retrieved on: 
Thursday, March 28, 2024
Pesticide, Sensitivity, Xenobiotic, Collaborative writing, Prevalence, ADHD, Cell, Risk, Inflammation, Patient, SAN, School, Anglo-French Wars, Tissue, Research, Miller, Child, Breast, Virus, University, Wane, Doctor of Philosophy, Pregnancy, Causality, Attention deficit hyperactivity disorder, Gulf War, B cell, EPA, CDC, University of Texas System, Fire, Toxicology, Workforce, Public health, TILT, Spectrum, Family, Histamine, Vaccine

SAN ANTONIO, March 27, 2024 /PRNewswire-PRWeb/ -- Autism and attention deficit hyperactivity disorder (ADHD) may be preventable if parents avoid toxic exposures and adopt interventions such as environmental house calls, according to a published study led by researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio).

Key Points: 
  • The findings build on a 2015 study by UT Health San Antonio that first linked chemical intolerance in patients with the risk of their children developing autism and ADHD.
  • "Up to now, most interventions have been behavioral or medical, after a child is diagnosed."
  • Still, they wrote, "The implications of this study, if confirmed, could be significant for preventive measures and early intervention strategies in families with parental chemical intolerance.
  • And the prevalence of ADHD has risen to one in eight children, also according to the CDC.